deltatrials
Unknown NA INTERVENTIONAL 2-arm NCT02701231

Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer

Sponsor: Chinese PLA General Hospital

Conditions Lung Neoplasms
Updated 6 times since 2017 Last updated: Mar 8, 2016 Started: Nov 30, 2015 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Lung Neoplasms, this trial is ongoing. The trial is conducted by Chinese PLA General Hospital and has accumulated 6 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotRecruiting~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown NA

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown NA

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown StatusUnknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status NA

    Status: RecruitingUnknown Status

  5. Jun 2018 — Jan 2021 [monthly]

    Recruiting NA

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Recruiting NA

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chinese PLA General Hospital
  • Shandong Provincial Hospital
  • Shandong University of Traditional Chinese Medicine
  • Xijing Hospital
Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .